2025 · 4th Quarter (Oct 1 - Dec 31)

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA)

Filed by DESIMONE CONSULTING, LLC.

Open official filing

Source-reported fields

Filing overview

Type: 4th Quarter - Report
Posted: Jan 17, 2026
Income: $40,000.00
Expenses: Not reported
Registrant: DESIMONE CONSULTING, LLC
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA)
Filing UUID: 2d3312fa-feeb-4af0-b0ba-adc572c7cdd0
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

PHA · Pharmacy

Issues related to patient access and pricing. Issues related to policy changes to Medicare Part D. Issues related to 340B reform. Issues related to the EPIC (Ensuring Pathways to Innovative Cures) Act, H.R.1492/S.832. Issues related to Most Favored Nation (MFN) policy. Issues related to PBM reform; H.R.4317, PBM Reform Act of 2025 and S.3345, PBM Price Transparency and Accountability Act.

Literal federal measure citations: H.R.1492, S.832, H.R.4317, S.3345

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.